Hiroaki Sato
About Hiroaki Sato
Hiroaki Sato is the Director of Portfolio Strategy of Hematology at Bristol Myers Squibb in Tokyo, Japan, with extensive experience in corporate strategy and product portfolio management within the pharmaceutical industry.
Director, Portfolio Strategy of Hematology at Bristol Myers Squibb
Hiroaki Sato currently serves as the Director of Portfolio Strategy in Hematology at Bristol Myers Squibb. In this role, based in Tokyo, Japan, he applies his extensive experience in corporate strategy and product portfolio management to advance the company's hematology pipeline. His leadership focuses on ensuring the strategic alignment and successful execution of the hematology portfolio, leveraging his deep knowledge of biotech and drug development processes.
Previous Roles and Experience at GSK
From 2006 to 2021, Hiroaki Sato was the Director of Portfolio Management/BD-Alliance/Strategy at GSK in Tokyo. Over his 15-year tenure, he specialized in managing development alliances and executing strategic initiatives. One notable achievement was his leadership in the dissolution of the GSK-DS Joint-Venture project. His role required significant cross-organizational issue resolution within the pharmaceutical industry, building a robust foundation for his current responsibilities.
Career Background at AstraZeneca and Kirin Brewery Co., Ltd.
Before his tenure at GSK, Hiroaki worked at AstraZeneca from 2002 to 2006 as Associate Director of Portfolio Management and Business Planning in Osaka, Japan. At AstraZeneca, he managed business planning operations and enhanced portfolio management practices. Prior to this, Hiroaki spent 12 years at Kirin Brewery Co., Ltd. in Tokyo, where he held the role of Manager of Strategic Business Planning, focusing on long-term strategic initiatives.
Education and Professional Development
Hiroaki Sato holds a PhD from The University of Tokyo, where he honed his expertise in scientific research and analytics. Complementing his technical background, he also earned an MBA from the MIT Sloan School of Management, studying from 1998 to 2000. His MBA equipped him with advanced skills in business management and corporate strategy, which he has effectively applied throughout his career in the pharmaceutical industry.
Expertise in Pharmaceutical and Biotech Sectors
Hiroaki Sato is recognized for his in-depth knowledge and experience in the pharmaceutical and biotech sectors. His expertise extends to managing complex drug development processes and product portfolios. He is skilled in forming and managing strategic alliances, particularly within the pharma business sector, and has a proven track record in resolving cross-organizational issues, making him a key asset in any strategic role.